Amylyx Pharmaceuticals (AMLX) Total Current Liabilities (2021 - 2025)
Historic Total Current Liabilities for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $25.8 million.
- Amylyx Pharmaceuticals' Total Current Liabilities fell 5216.36% to $25.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.8 million, marking a year-over-year decrease of 5216.36%. This contributed to the annual value of $28.4 million for FY2024, which is 6537.63% down from last year.
- Latest data reveals that Amylyx Pharmaceuticals reported Total Current Liabilities of $25.8 million as of Q3 2025, which was down 5216.36% from $21.4 million recorded in Q2 2025.
- Amylyx Pharmaceuticals' 5-year Total Current Liabilities high stood at $91.6 million for Q1 2024, and its period low was $17.4 million during Q4 2021.
- For the 5-year period, Amylyx Pharmaceuticals' Total Current Liabilities averaged around $44.0 million, with its median value being $39.1 million (2022).
- As far as peak fluctuations go, Amylyx Pharmaceuticals' Total Current Liabilities soared by 16792.94% in 2022, and later plummeted by 8043.19% in 2025.
- Quarter analysis of 5 years shows Amylyx Pharmaceuticals' Total Current Liabilities stood at $17.4 million in 2021, then soared by 167.93% to $46.6 million in 2022, then surged by 76.02% to $82.0 million in 2023, then crashed by 65.38% to $28.4 million in 2024, then decreased by 9.21% to $25.8 million in 2025.
- Its Total Current Liabilities stands at $25.8 million for Q3 2025, versus $21.4 million for Q2 2025 and $17.9 million for Q1 2025.